Isotretinoin Embryopathy—A Continuing Problem

Journal of Clinical Pharmacology - Tập 29 Số 5 - Trang 463-465 - 1989
Elizabeth B. Rappaport1,2, Mary M. Knapp2
1347 Prospect Ave., Princeton, NJ 08540.
2New Jersey Department of Health Special Child Health Services Trenton, NJ.

Tóm tắt

First trimester exposure to isotretinoin is associated with an estimated 20% risk of major fetal malformations. Product labeling in force up to August 1988 included a statement that the drug is contraindicated in pregnancy and suggested procedures for prescribing physicians to follow to prevent inadvertent first trimester exposure to the product. This limited educational intervention did not prevent the continued occurrence of isotretinoin‐related birth defects. The effectiveness of recent changes in the package labeling in preventing such birth defects remains to he demonstrated. Two infants with major birth defects associated with first trimester exposure to isotretinoin (Accutane, Roche Laboratories**) were reported to the New Jersey Birth Defects Registry within 6 months. Stimulated by these reports, we sought additional cases in New Jersey and found three. We here describe these five cases of isotretinoin embryopathy, including available information on the circumstances which led to maternal use of isotretinoin during the first trimester of pregnancy. In response to a preliminary report of these cases1 and to investigations by epidemiologists at the U.S. Food and Drug Administration (FDA), the manufacturer altered the package labeling.2 The revised product information includes a more prominent “contraindication and warning” section and a new “patient information/consent” section. The effectiveness of this educational intervention should be evaluated.

Từ khóa


Tài liệu tham khảo

Centers for Disease Control, 1988, Birth Defects Caused by Isotretinoin—New Jersey, MMWR, 37, 171

1988, Product Information Accutane (isotretinoin/Roche) capsules

10.1056/NEJM198510033131401

Cruz E, 1984, Multiple congenital malformations associated with maternal isotretinoin therapy, Pediatrics, 74, 428, 10.1542/peds.74.3.428

1983, Physicians' Desk Reference, 1643

10.1002/tera.1420330315

10.1016/S0140-6736(83)90538-X

10.1016/S0140-6736(84)92866-6

10.1016/S0140-6736(84)91954-8

10.1001/jama.1984.03340480049027

Lammer EJ, 1987, Risk of major malformation among human fetuses exposed to isotretinoin, Teratology, 35, 68a

1984, Physicians' Desk Reference, 1616

1985, Physicians' Desk Reference, 1665

1986, Physicians' Desk Reference, 1469

1988, Physicians' Desk Reference, 1705

Anonymous.Anti‐acne drug endangers fetus. Consumers Digest SeptemberOctober 1984;15.

Anonymous.Danger from acne medication. USA Today October 1984;13.

FreidfeldK EngelmayerS:Use only as directed. Health April 1984;58.

10.2105/AJPH.77.12.1518

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 29 Số 5

463-465

Thông tin tác giả